Traditionally, the pharmaceutical industry has employed batch processes to manufacture solid oral dosage forms. In batch manufacturing, the typical lead time of a solid oral dosage form can be up to one year, which can result in drug shortages in case of a significant change in the demand. In addition to major reductions in the production time and footprint, continuous manufacturing decreases the manufacturing costs significantly, as well as the number of unit operations involved. Federica Casati at IMA Active notes that continuous manufacturing can be coupled with in-line analytics to monitor the process material constantly and reject a much smaller quantity in case of an anomaly.